NCT06767462 An Ophthalmic Safety Study in Patients With Breast Cancer
| NCT ID | NCT06767462 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Ophthalmic Safety in Patients With Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 160 participants |
| Start Date | 2025-03-04 |
| Primary Completion | 2027-07-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 160 participants in total. It began in 2025-03-04 with a primary completion date of 2027-07-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To assess ophthalmic health in parallel cohorts of patients with breast cancer
Eligibility Criteria
Inclusion Criteria: 1. Signed informed consent in the qualifying study. 2. Signed informed consent in the ophthalmic study prior to any ophthalmic study specific assessments and procedures. 3. Completed the baseline ophthalmic examination for this study before the first dose in the qualifying study. 4. Meets all the eligibility criteria in the qualifying study Exclusion Criteria: 1. Patients not randomized and not receiving study assigned treatment in a qualifying study. 2. Patients with contraindications to any ophthalmic procedure required by the study or sensitivity/allergy to pupil dilating agents. 3. Judgement by the investigator that the patient should not participate in the ophthalmic study if the patient is unlikely to comply with study procedures, restrictions, and requirements
Frequently Asked Questions
Who can join the NCT06767462 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 130 Years, studying Ophthalmic Safety in Patients With Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06767462 currently recruiting?
Yes, NCT06767462 is actively recruiting participants. Visit ClinicalTrials.gov or contact AstraZeneca to inquire about joining.
Where is the NCT06767462 trial being conducted?
This trial is being conducted at La Jolla, United States, Palo Alto, United States, San Diego, United States, Iowa City, United States and 1 additional location.
Who is sponsoring the NCT06767462 clinical trial?
NCT06767462 is sponsored by AstraZeneca. The trial plans to enroll 160 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.